We are exclusively focused on developing the leading treatment for acute infectious conjunctivitis (also known as pink eye).
Our lead product candidate, OKG-0303, is being developed to treat acute infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial.